Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 8, 2019, discloses that Perrigo Company plc (the "Company") has entered into a definitive agreement to acquire Ranir Global Holdings, LLC ("Ranir"). Ranir is a leading global supplier of private label and branded oral care products headquartered in Grand Rapids, Michigan. The transaction is intended to expand the Company's oral care portfolio.
Key Financial Metrics and Transaction Structure
- Transaction Value: $750 million in cash, subject to purchase price adjustments.
- Structure: The acquisition is structured as a two-part transaction involving the purchase of equity in a blocker entity followed by a merger, resulting in Ranir becoming an indirect, wholly-owned subsidiary of Perrigo.
- Funding Sources: The Company intends to fund the transaction with approximately $450 million of cash on hand and the remaining balance through short-term debt.
- Financial Basis: The purchase price is on a cash-free, debt-free basis and subject to adjustments for tax obligations or benefits allocable to periods through the closing date.
Material Changes and Conditions
The filing does not report changes to historical financial performance metrics such as revenue or profit for a specific period. The primary material change is the commitment to the $750 million acquisition. The transaction is subject to several closing conditions, including:
- Termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Clearance under applicable German antitrust law.
- Absence of certain legal proceedings.
- No material adverse effect on Ranir since the date of the Agreement.
Outlook, Risks, and Management Commentary
Timeline: The Company expects to close the transaction by the end of the third quarter of fiscal year 2019.
Risks and Contingencies:
- Regulatory Risk: Closing is contingent on antitrust approvals in the U.S. and Germany. The parties are not required to agree to structural or conduct remedies or to litigate to obtain these approvals.
- Termination Rights: Either party may terminate the agreement under certain circumstances, including an uncured material breach or if the transaction is not consummated within 240 days of signing.
- Indemnification: The Company has purchased a representation and warranty insurance policy. Post-closing, the sole recourse for breaches regarding Ranir and the Blocker Seller will be against this policy.
Key Facts for Investor Verification
- Verify the Company's ability to secure the necessary short-term debt to fund the balance of the $750 million purchase price.
- Monitor the status of antitrust clearance in the U.S. and Germany, as failure to obtain these could delay or terminate the deal.
- Confirm the expected closing date remains within the third quarter of fiscal year 2019.
- Assess the impact of the acquisition on the Company's liquidity and leverage ratios upon closing.